Evidence map›Paper›PMID 42891071›Full record

ArticleiScience2026

Lipid-based mRNA chimeric antigen receptor T cells for enhanced

Haixia Gao, Yuan Fang, Zhidan Tian, Chuanxin Guo, Pei Wang, Tao Liu, Yan Sun, Pingjing Zhang, Qijun Qian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haixia GaoShanghai Mengchao Cancer Hospital and School of Medicine, Shanghai University, Shanghai, China.
Yuan FangShanghai Mengchao Cancer Hospital and School of Medicine, Shanghai University, Shanghai, China.
Zhidan TianShanghai Cell Therapy Group Co., Ltd., Shanghai, China.
Chuanxin GuoShanghai Cell Therapy Group Co., Ltd., Shanghai, China.
Pei WangShanghai Mengchao Cancer Hospital and School of Medicine, Shanghai University, Shanghai, China.
Tao LiuShanghai Cell Therapy Group Co., Ltd., Shanghai, China.
Yan SunShanghai Mengchao Cancer Hospital and School of Medicine, Shanghai University, Shanghai, China.
Pingjing ZhangShanghai Cell Therapy Group Co., Ltd., Shanghai, China.
Qijun QianShanghai Mengchao Cancer Hospital and School of Medicine, Shanghai University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapy provides substantial clinical benefits in hematologic malignancies. However, cell engineering using conventional viral vectors is costly, labor intensive, and prone to safety risks, while electroporation-induced cellular damage limits manufacturing scalability. This study reports a safe, high-efficiency, nonviral platform for generating mRNA-engineered CAR T cells. Herein, eight ionizable lipids are synthesized and formulated into lipid nanoparticles. Systematic screening and structural optimization identified lipid 6 as the lead candidate. Transfection efficiency is validated by delivering enhanced green fluorescent protein (

Indexed as

cell engineeringchimeric antigen receptor T cellsimmunotherapylipid nanoparticlesmRNA delivery

Identifiers

PMID42891071
PMCPMC13673102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.